What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call

Aquestive Therapeutics reported Q3 revenue of $7.6M, down from $12.8M YoY, due to Suboxone order fluctuations. The company discussed payer negotiations for Anaphylm, a potential differentiator in epinephrine treatment. Aquestive also announced a licensing deal for Libervant with Eton Pharmaceuticals, receiving a $10M upfront payment. The company expects to end 2026 with over $70M in cash and maintained its 2026 revenue outlook of $46M-$50M.

Original reporting
Published Nov 4, 2026, 4:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$AQSTBearishMed
01

Why it matters

The earnings miss may trigger short‑covering and price declines, but the licensing deal and cash runway could mitigate downside.

02

Market read

Micro‑cap biotech earnings with a revenue decline and loss, offset by a licensing upfront payment and cash runway.

03

What to watch

Potential upside from upcoming Anaphylm approval and AdrenaVerse pipeline not reflected in current price.

Relevance 6/10Novelty 7/10Timing: post‑earnings release today

Background

Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharma focused on oral film delivery, with products Libervant and Exservan already on market.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

Q3 earnings release shows revenue down 40% YoY, net loss widening and guidance unchanged, plus a $10M upfront licensing payment.

Expected impact

likely downward pressure as investors digest lower revenue and higher loss.

Evidence & confidence

The company reported a sharp revenue decline, a larger net loss, and only modest cash balance, which typically triggers sell‑offs in micro‑cap pharma stocks.

Market effects

Highlights continued pressure on specialty pharma micro‑caps with pending FDA reviews.

Limited to U.S. biotech investors; no broader market effect.

Minimal global impact beyond niche biotech community.

Counterpoint

The $10M upfront payment and potential $75M strategic funding could provide runway, suggesting upside if the pipeline de‑risked.

Key entities

  • Eton Pharmaceuticals

    Exclusive U.S. commercialization rights holder for Libervant.

  • Oaktree

    Provider of a term‑loan facility referenced in the guidance.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.